These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 12534951)

  • 21. "Hard" and "soft" lesions underlying the HLA class I alterations in cancer cells: implications for immunotherapy.
    Garrido F; Cabrera T; Aptsiauri N
    Int J Cancer; 2010 Jul; 127(2):249-56. PubMed ID: 20178101
    [TBL] [Abstract][Full Text] [Related]  

  • 22. T-cell-receptor-like antibodies - generation, function and applications.
    Dahan R; Reiter Y
    Expert Rev Mol Med; 2012 Feb; 14():e6. PubMed ID: 22361332
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immunodominance across HLA polymorphism: implications for cancer immunotherapy.
    Kim CJ; Parkinson DR; Marincola F
    J Immunother; 1998 Jan; 21(1):1-16. PubMed ID: 9456431
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Vaccination of metastatic colorectal cancer patients with matured dendritic cells loaded with multiple major histocompatibility complex class I peptides.
    Kavanagh B; Ko A; Venook A; Margolin K; Zeh H; Lotze M; Schillinger B; Liu W; Lu Y; Mitsky P; Schilling M; Bercovici N; Loudovaris M; Guillermo R; Lee SM; Bender J; Mills B; Fong L
    J Immunother; 2007 Oct; 30(7):762-72. PubMed ID: 17893568
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficient antigen gene transduction using Arg-Gly-Asp fiber-mutant adenovirus vectors can potentiate antitumor vaccine efficacy and maturation of murine dendritic cells.
    Okada N; Saito T; Masunaga Y; Tsukada Y; Nakagawa S; Mizuguchi H; Mori K; Okada Y; Fujita T; Hayakawa T; Mayumi T; Yamamoto A
    Cancer Res; 2001 Nov; 61(21):7913-9. PubMed ID: 11691812
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Dendritic type, accessory cells within the mammalian thymic microenvironment. Antigen presentation in the dendritic neuro-endocrine-immune cellular network.
    Bodey B; Bodey B; Kaiser HE
    In Vivo; 1997; 11(4):351-70. PubMed ID: 9292303
    [TBL] [Abstract][Full Text] [Related]  

  • 27. DNA vaccination: antigen presentation and the induction of immunity.
    Shedlock DJ; Weiner DB
    J Leukoc Biol; 2000 Dec; 68(6):793-806. PubMed ID: 11129646
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Modified vaccinia virus Ankara-infected dendritic cells present CD4+ T-cell epitopes by endogenous major histocompatibility complex class II presentation pathways.
    Thiele F; Tao S; Zhang Y; Muschaweckh A; Zollmann T; Protzer U; Abele R; Drexler I
    J Virol; 2015 Mar; 89(5):2698-709. PubMed ID: 25520512
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy.
    Kranz LM; Diken M; Haas H; Kreiter S; Loquai C; Reuter KC; Meng M; Fritz D; Vascotto F; Hefesha H; Grunwitz C; Vormehr M; Hüsemann Y; Selmi A; Kuhn AN; Buck J; Derhovanessian E; Rae R; Attig S; Diekmann J; Jabulowsky RA; Heesch S; Hassel J; Langguth P; Grabbe S; Huber C; Türeci Ö; Sahin U
    Nature; 2016 Jun; 534(7607):396-401. PubMed ID: 27281205
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Antigen presentation and T cell stimulation by dendritic cells.
    Guermonprez P; Valladeau J; Zitvogel L; Théry C; Amigorena S
    Annu Rev Immunol; 2002; 20():621-67. PubMed ID: 11861614
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Tumour-specific CTL response requiring interactions of four different cell types and recognition of MHC class I and class II restricted tumour antigens.
    Schirrmacher V; Schild HJ; Gückel B; von Hoegen P
    Immunol Cell Biol; 1993 Aug; 71 ( Pt 4)():311-26. PubMed ID: 7901150
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Present Yourself! By MHC Class I and MHC Class II Molecules.
    Rock KL; Reits E; Neefjes J
    Trends Immunol; 2016 Nov; 37(11):724-737. PubMed ID: 27614798
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Therapeutic gene modified cell based cancer vaccines.
    Kozłowska A; Mackiewicz J; Mackiewicz A
    Gene; 2013 Aug; 525(2):200-7. PubMed ID: 23566846
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Forcing tumor cells to present their own tumor antigens to the immune system: a necessary design for an efficient tumor immunotherapy.
    Humphreys RE; Hillman GG; von Hofe E; Xu M
    Cell Mol Immunol; 2004 Jun; 1(3):180-5. PubMed ID: 16219165
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immune responses to human tumors: development of tumor vaccines.
    Platsoucas CD; Fincke JE; Pappas J; Jung WJ; Heckel M; Schwarting R; Magira E; Monos D; Freedman RS
    Anticancer Res; 2003; 23(3A):1969-96. PubMed ID: 12894571
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cancer immunotherapy takes a multi-faceted approach to kick the immune system into gear.
    Dimberu PM; Leonhardt RM
    Yale J Biol Med; 2011 Dec; 84(4):371-80. PubMed ID: 22180675
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immunohistochemical characterisation of immunological changes at the tumour site after chemo-immunotherapy with doxorubicin, interleukin-2 and interferon-gamma.
    Lumsden AJ; Codde JP; Van der Meide PH; Gray BN
    Anticancer Res; 1996; 16(3A):1145-54. PubMed ID: 8702226
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Selective transport of internalized antigens to the cytosol for MHC class I presentation in dendritic cells.
    Rodriguez A; Regnault A; Kleijmeer M; Ricciardi-Castagnoli P; Amigorena S
    Nat Cell Biol; 1999 Oct; 1(6):362-8. PubMed ID: 10559964
    [TBL] [Abstract][Full Text] [Related]  

  • 39. CD11c+ blood dendritic cells induce antigen-specific cytotoxic T lymphocytes with similar efficiency compared to monocyte-derived dendritic cells despite higher levels of MHC class I expression.
    Radford KJ; Turtle CJ; Kassianos AJ; Hart DN
    J Immunother; 2006; 29(6):596-605. PubMed ID: 17063122
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Enhanced major histocompatibility complex class I-dependent presentation of antigens modified with cationic and fusogenic peptides.
    Laus R; Graddis TJ; Hakim I; Vidovic D
    Nat Biotechnol; 2000 Dec; 18(12):1269-72. PubMed ID: 11101805
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.